Blog

Patrick Hwu: Chat with Lilit Karapetyan about her work with TIL therapy for melanoma

Photo of Patrick Hwu and Lilit Karapetyan

May 30, 2024, 15:35

Patrick Hwu: Chat with Lilit Karapetyan about her work with TIL therapy for melanoma

Rick Buck Chief Communications Officer/Vice President of Communications and Public Relations at AACR, shared a post by Patrick Hwu, on X, adding:

”Thanks for supporting NCRM24 Patrick Hwu and AACR efforts around it with our nation’s cancer centers. We appreciate Moffitt Cancer Center and your communications efforts in support of cancer research.”

Quoting Patrick Hwu’s post:

”In honor of Cancer Research Month, I recently sat down to chat with Lilit Karapetyan, a melanoma medical oncologist at Moffitt Cancer Center, about her work with TIL therapy for melanoma.”

View attached video.
Source: Rick Buck/X and Patrick Hwu/X

Patrick Hwu, MD, currently serves as the President and CEO of Moffitt Cancer Center. With a focus on understanding the dynamics between tumors and the immune system, Dr. Hwu’s research has been pivotal in advancing gene-modified T cell therapy. He notably contributed seminal work on the development of the first chimeric antigen receptor aimed at combating cancer. His research portfolio extends to vaccines, adoptive T-cell therapies, and mechanisms of immune resistance.

Before joining, Dr. Hwu held numerous leadership roles at The University of Texas MD Anderson Cancer Center for over 17 years. Notably, he served as the inaugural Chairman of the Department of Melanoma Medical Oncology in 2003, as well as the Associate Director of the Center for Cancer Immunology Research. Additionally, he chaired the Department of Sarcoma Medical Oncology, demonstrating his commitment to advancing cancer treatment and research.